Cargando…

Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions

Infections of the Coronavirus SARS-CoV-2 continue to spread around the globe, causing Coronavirus Disease (COVID)-19. Infected people are at risk of developing acute interstitial pneumonia, which can result in lethal complications, particularly in patients with pre-existing co-morbidities. Novel pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Renn, Marcel, Bartok, Eva, Zillinger, Thomas, Hartmann, Gunther, Behrendt, Rayk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219947/ https://www.ncbi.nlm.nih.gov/pubmed/34171328 http://dx.doi.org/10.1016/j.pharmthera.2021.107931

Ejemplares similares

RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection
por: Marx, Samira, et al.
Publicado: (2022)

Correlation between a quantitative anti‐SARS‐CoV‐2 IgG ELISA and neutralization activity
por: Dolscheid‐Pommerich, Ramona, et al.
Publicado: (2021)

RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma
por: Lambing, Silke, et al.
Publicado: (2023)

Spike S2 Subunit: The Dark Horse in the Race for Prophylactic and Therapeutic Interventions against SARS-CoV-2
por: Ng, Kim Tien, et al.
Publicado: (2021)

Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection
por: Li, Wei, et al.
Publicado: (2020)

Animal models for SARS-CoV-2 and SARS-CoV-1 pathogenesis, transmission and therapeutic evaluation
por: Saravanan, Udhaya Bharathy, et al.
Publicado: (2022)

Possible Prophylactic Approach for SARS-CoV-2 Infection by Combination of Melatonin, Vitamin C and Zinc in Animals
por: Fatima, Sabiha, et al.
Publicado: (2020)

Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro
por: Clementi, Nicola, et al.
Publicado: (2020)

Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
por: Wang, Shuang, et al.
Publicado: (2020)

A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic
por: Shapira, Tirosh, et al.
Publicado: (2022)

An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight
por: Shoaib, Shoaib, et al.
Publicado: (2023)

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics
por: Zhao, Shaojuan, et al.
Publicado: (2021)

Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets
por: de Wit, Emmie, et al.
Publicado: (2018)

Insights into the evolutionary and prophylactic analysis of SARS-CoV-2: A review
por: Akram, Fatima, et al.
Publicado: (2022)

1143. Prophylactic and Therapeutic Activity of AZD7442 (Tixagevimab/Cilgavimab) in SARS-CoV-2 Hamster Challenge Models
por: Loo, Yueh-Ming, et al.
Publicado: (2022)

A Comprehensive Review of Animal Models for Coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV
por: Singh, Ashutosh, et al.
Publicado: (2020)

Investigation of Animal Reservoir(s) of SARS-CoV
por: Hu, Zhihong, et al.
Publicado: (2008)

Animal models for SARS-CoV-2
por: Lee, Chung-Young, et al.
Publicado: (2021)

FXR inhibition: an innovative prophylactic strategy against SARS-CoV-2 infection
por: Li, Zhe, et al.
Publicado: (2023)

The Coronaviruses of Animals and Birds: Their Zoonosis, Vaccines, and Models for SARS-CoV and SARS-CoV2
por: Alluwaimi, Ahmed M., et al.
Publicado: (2020)

Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2
por: Garcia-del-Barco, Diana, et al.
Publicado: (2021)

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo
por: Zhang, Zhaoyong, et al.
Publicado: (2021)

Exploring peptide studies related to SARS-CoV to accelerate the development of novel therapeutic and prophylactic solutions against COVID-19
por: Madhavan, Maya, et al.
Publicado: (2021)

Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants
por: Li, Qi, et al.
Publicado: (2022)

G-rich DNA-induced stress response blocks type-I-IFN but not CXCL10 secretion in monocytes
por: Herzner, Anna-Maria, et al.
Publicado: (2016)

Mouse Adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge
por: Muruato, Antonio, et al.
Publicado: (2021)

Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge
por: Muruato, Antonio, et al.
Publicado: (2021)

Animal models and vaccines for SARS-CoV infection
por: Roberts, Anjeanette, et al.
Publicado: (2008)

Animal models of SARS-CoV-2 transmission
por: de Vries, Rory D, et al.
Publicado: (2021)

An Overview of SARS-CoV-2 and Animal Infection
por: Mahdy, Mohamed A. A., et al.
Publicado: (2020)

Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department
por: Brown, Cortlyn, et al.
Publicado: (2020)

Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models
por: Takeshita, Masaru, et al.
Publicado: (2022)

First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants
por: Titong, Allison, et al.
Publicado: (2022)

Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV
por: Xu, Jiabao, et al.
Publicado: (2020)

SARS-CoV-2 in animals: From potential hosts to animal models
por: Michelitsch, Anna, et al.
Publicado: (2021)

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
por: de Wit, Emmie, et al.
Publicado: (2020)

Structural insights of key enzymes into therapeutic intervention against SARS-CoV-2
por: Shahid, Munazza, et al.
Publicado: (2021)

Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions
por: Shah, Masaud, et al.
Publicado: (2021)

Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo
por: Li, Mengjiao, et al.
Publicado: (2022)

Human-Animal Interaction and the Emergence of SARS-CoV-2
por: Hassani, Asma, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l9h5en1kim4uqss5vqju85gtmt